RECKITT BENCKIS/S (OTCMKTS:RBGLY) Coverage Initiated at HSBC

Analysts at HSBC assumed coverage on shares of RECKITT BENCKIS/S (OTCMKTS:RBGLY) in a note issued to investors on Friday, June 28th, Briefing.com Automated Import reports. The brokerage set a “buy” rating on the stock.

Separately, Zacks Investment Research cut shares of Green Plains from a “hold” rating to a “strong sell” rating in a research note on Thursday, June 27th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $19.00.

Shares of RBGLY stock traded down $0.21 on Friday, reaching $16.50. 70,942 shares of the company were exchanged, compared to its average volume of 181,737. The company has a market cap of $59.11 billion, a P/E ratio of 18.33, a price-to-earnings-growth ratio of 9.60 and a beta of 0.75. The firm has a 50-day moving average of $16.22. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.48 and a current ratio of 0.65. RECKITT BENCKIS/S has a 1 year low of $14.64 and a 1 year high of $18.85.

About RECKITT BENCKIS/S

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

Recommended Story: Bond

Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.